Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy.
Remenár É, Dóczi R, Dirner A, Sipos A, Perjési A, Tihanyi D, Vodicska B, Lakatos D, Horváth K, Kajáry K, Schwáb R, Déri J, Lengyel CG, Várkondi E, Vályi-Nagy I, Peták I. Remenár É, et al. Among authors: sipos a. JCO Precis Oncol. 2022 Jan;6:e2100344. doi: 10.1200/PO.21.00344. JCO Precis Oncol. 2022. PMID: 35005996 No abstract available.
Targeted drug combination therapy design based on driver genes.
Zsákai L, Sipos A, Dobos J, Erős D, Szántai-Kis C, Bánhegyi P, Pató J, Őrfi L, Matula Z, Mikala G, Kéri G, Peták I, Vályi-Nagy I. Zsákai L, et al. Among authors: sipos a. Oncotarget. 2019 Sep 3;10(51):5255-5266. doi: 10.18632/oncotarget.26985. eCollection 2019 Sep 3. Oncotarget. 2019. PMID: 31523388 Free PMC article.
Lead selection and characterization of antitubercular compounds using the Nested Chemical Library.
Sipos A, Pató J, Székely R, Hartkoorn RC, Kékesi L, Őrfi L, Szántai-Kis C, Mikušová K, Svetlíková Z, Korduláková J, Nagaraja V, Godbole AA, Bush N, Collin F, Maxwell A, Cole ST, Kéri G. Sipos A, et al. Tuberculosis (Edinb). 2015 Jun;95 Suppl 1:S200-6. doi: 10.1016/j.tube.2015.02.028. Epub 2015 Feb 28. Tuberculosis (Edinb). 2015. PMID: 25801335
Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
Czudor Z, Balogh M, Bánhegyi P, Boros S, Breza N, Dobos J, Fábián M, Horváth Z, Illyés E, Markó P, Sipos A, Szántai-Kis C, Szokol B, Őrfi L. Czudor Z, et al. Among authors: sipos a. Bioorg Med Chem Lett. 2018 Feb 15;28(4):769-773. doi: 10.1016/j.bmcl.2018.01.002. Epub 2018 Jan 2. Bioorg Med Chem Lett. 2018. PMID: 29329658
Novel, selective CDK9 inhibitors for the treatment of HIV infection.
Németh G, Varga Z, Greff Z, Bencze G, Sipos A, Szántai-Kis C, Baska F, Gyuris A, Kelemenics K, Szathmáry Z, Minárovits J, Kéri G, Orfi L. Németh G, et al. Among authors: sipos a. Curr Med Chem. 2011;18(3):342-58. doi: 10.2174/092986711794839188. Curr Med Chem. 2011. PMID: 21143121
Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.
Németh G, Greff Z, Sipos A, Varga Z, Székely R, Sebestyén M, Jászay Z, Béni S, Nemes Z, Pirat JL, Volle JN, Virieux D, Gyuris Á, Kelemenics K, Ay E, Minarovits J, Szathmary S, Kéri G, Orfi L. Németh G, et al. Among authors: sipos a. J Med Chem. 2014 May 22;57(10):3939-65. doi: 10.1021/jm401742r. Epub 2014 May 2. J Med Chem. 2014. PMID: 24742150
Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors.
Baska F, Szabadkai I, Sipos A, Breza N, Szántai-Kis C, Kékesi L, Garamvölgyi R, Nemes Z, Baska F, Neumann L, Torka R, Ullrich A, Kéri G, Orfi L. Baska F, et al. Among authors: sipos a. Curr Med Chem. 2014 Jun;21(17):1938-55. doi: 10.2174/0929867321666140304152606. Curr Med Chem. 2014. PMID: 24606495
166 results